The DEXYCU Diaries

Firsthand Thoughts and Expertise from Leading Ophthalmic Surgeons as They Share Their Experiences Administering DEXYCUi®

INDICATION AND USAGE
DEXYCU® (dexamethasone intraocular suspension) 9% is indicated for the treatment of postoperative inflammation.
Please see Important Safety Information below and link to full Prescribing Information.

What has been your experience with DEXYCU?

What does it mean to you to have an FDA-approved drop-free option?

What advice would you give to surgeons new to DEXYCU?

What are your thoughts on being able to deliver an anti-inflammatory treatment directly at the site?

What has been your experience with DEXYCU since launch?

What advice would you give to surgeons new to DEXYCU?

What are your thoughts on being able to deliver an anti-inflammatory treatment directly at the site?

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
None.

Please see continued Important Safety Information below and link to full Prescribing Information.

Speakers

Matossian

Cynthia Matossian, MD, FACS

Cynthia Matossian, MD, FACS is the founder and medical director of Matossian Eye Associates with multiple offices in PA and NJ. She specializes in refractive cataract surgery and dry eye disease.

Ayres

Brandon Ayres, MD

Brandon Ayres, MD, has been part of the Cornea Service at Wills Eye Hospital since 2005, and has been part of Ophthalmic Partners since 2007. He serves as an Assistant Surgeon at Wills Eye Hospital and is an instructor at Jefferson Medical College, Thomas Jefferson University.

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS

Increase in Intraocular Pressure
  • Prolonged use of corticosteroids, including DEXYCU, may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision
  • Steroids should be used with caution in the presence of glaucoma
Delayed Healing
  • The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation
  • In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of corticosteroids
Exacerbation of Infection
  • The use of DEXYCU, as with other ophthalmic corticosteroids, is not recommended in the presence of most active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal disease of ocular structures
  • Use of a corticosteroid in the treatment of patients with a history of herpes simplex requires caution and may prolong the course and may exacerbate the severity of many viral infections
  • Fungal infections of the cornea are particularly prone to coincidentally develop with long-term local steroid application and must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate
  • Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection
Cataract Progression
  • The use of corticosteroids in phakic individuals may promote the development of posterior subcapsular cataracts
ADVERSE REACTIONS
The most commonly reported adverse reactions occurred in 5-15% of subjects and included increases in intraocular pressure, corneal edema and iritis
 

Please click here for Full Prescribing Information.